A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Phase 1 Terminated 104 enrolled Eli Lilly and Company

RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3509754 gets into the bloodstream and how long it takes the body to eliminate it.

Timeline

Start: 2020-10-20
Primary completion: 2022-10-14
Completion: 2022-10-14

Outcome

Outcome not reported

Stopped: “Terminated due to safety findings”

Publications

Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study. Clin Pharmacol Ther. 2024 May;115(5):1152-1161. doi: 10.1002/cpt.3185. Epub 2024 Jan 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	LY3509754	Small molecule	10 mg	Oral
Subject	LY3509754	Small molecule	30 mg	Oral
Subject	LY3509754	Small molecule	100 mg	Oral
Subject	LY3509754	Small molecule	300 mg	Oral
Subject	LY3509754	Small molecule	400 mg	Oral
Subject	LY3509754	Small molecule	1000 mg	Oral
Subject	LY3509754	Small molecule	2000 mg	Oral
Subject	Midazolam	Small molecule	1.2 mg	Oral

Indications

No indication recorded.